• Home
  • >>>>>>>>>>>>> 2026 & BEYOND MASTER PLAN >>>>>>>>>>>>>>>>
  • Virtual Data Room (VDR) for Strategic Customized Slide Decks
  • TRAINABLE DATA ASSETS IN CORPORATE LEGACY & ORGANIZATION’s STRATEGIC MEMORY (2012 – 2025)
  • 2.0 LPBI Executive Summary
  • 1.0 LPBI Executive Summary
  • Founder’s Vision
  • Portfolio of IP Assets
  • Knowledge PORTALS System (KPS)
  • 1.0 LPBI – 2012-2020 VISTA
  • LPBI Group’s History
  • 2.0 LPBI – 2021-2025 VISION
  • BioMed e-Series
  • Press Coverage
  • Investor Relations
  • Our TEAM
  • Founder’s Bio
  • Funding, Deals & Partnerships
  • 1.0 LPBI Group News
  • 1.0 LPBI CALENDAR
  • 2.0 LPBI Group News
  • Testimonials about LPBI
  • DrugDiscovery @LPBI Group
  • Medical 3D Printing
  • e-VOICES Podcasting
  • LPBI Newsletters
  • Customer Surveys
  • Health Care INVESTOR’s Corner ($)
  • 2021 Summer Internship Portal
  • 2021-2025 Medical Text Analysis (NLP)
  • Artificial Intelligence: Genomics & Cancer
  • Blockchain Transactions Network Ecosystem
  • 1.0 LPBI Brochure
  • 2.0 LPBI Brochure
  • 2.0 LPBI – Calendar of Zooms
  • Coronavirus, SARS-CoV-2 Portal
  • LPBI India
  • SOP Web STAT
  • Synthetic Biology in Drug Discovery
  • Certificate One Year
  • NFT: Redefined Format of IP Assets
  • Audio English-Spanish: BioMed e-Series
  • Five Bilingual BioMed e-Series
  • Press Releases
  • Intangibles CIM
  • BioMed Audio Podcast Library @LPBI Group
  • Medical School Education: Use of LPBI Group’s Contents
  • ChatGPT + Wolfram PlugIn
  • Medicine with GPT-4 & ChatGPT
  • AGI, generativeAI, Grok, DeepSeek & Expert Models in Healthcare
  • Multimodal Healthcare Foundation Model
  • Cell Therapy in Regenerative Medicine, 2026 and Beyond
  • Contact Us

Leaders in Pharmaceutical Business Intelligence Group, LLC, Doing Business As LPBI Group, Newton, MA

Healthcare analytics, AI solutions for biological big data, providing an AI platform for the biotech, life sciences, medical and pharmaceutical industries, as well as for related technological approaches, i.e., curation and text analysis with machine learning and other activities related to AI applications to these industries.

Feeds:
Posts
Comments

Subsidiary 3: Medical 3D BioPrinting – M3DP

SUBSIDIARY #3

Medical 3D BioPrinting 

M3DP

http://pharmaceuticalintelligence.com/medical-3d-printing/

HQS – Boston, MA

HQS – Lausanne, Switzerland

  • Ontology Building for Medical 3D Printing: The Team @ Leaders in Pharmaceutical Business Intelligence (LPBI)
  • Cardiovascular Applications of 3D BioPrinting

Using 3D printed models for planning and guidance during endovascular intervention (VIDEO)

 VIEW VIDEO

http://www.3dbioprintingconference.com/surgery/using-3d-printed-models-for-planning-and-guidance-during-endovascular-intervention-video/

Bioprinted Valves That Grow: How 3D Printing is Transforming Heart Surgery (VIDEO)

VIEW VIDEO

http://www.3dbioprintingconference.com/3d-bioprinting/bioprinted-valves-that-grow-how-3d-printing-is-transforming-heart-surgery/

Matrix Organization

http://pharmaceuticalintelligence.com/2015/08/26/lpbis-m3dp-matrix-organization/

Repository of Resources on M3DP

http://pharmaceuticalintelligence.com/2015/08/18/repository-for-lpbis-initiative-on-medical-3d-printing/

HQS – Boston, MA – Aviva Lev-Ari, PhD, RN, Interim COO

HQS – Lausanne, Switzerland – Gerard Loiseau, ESQ – Strategic Planning & Departmental Finance

  • Applications in 3D BioPrinting

http://pharmaceuticalintelligence.com/2015/08/15/twelve-lecture-series-on-medical-3d-printing-applications-technologies-by-lpbis-medical-3d-printing-team/

  • Product Concept  – Dr. Pearlman

  1. StopMI
  2. Robotic Glove
  • BioMEMS

We are seeking a Private Equity Investor interested in Medical 3D BioPrinting to invest for an Equity position and provide Business Development and Finance capabilities to a Technical Team of Scientists (PhDs, MD/PhDs) and BioEngineers in Tissue Engineering, Pharmaceutical and Medical Devices (Cardiovascular and Orthopedic) using 3D BioPrinting.

  • Seeking $20Million for three Departments

Like this:

Like Loading…

This page has the following sub pages.

  • TEAM PRESENTATIONS: 8/2015 – 12/2015
  • BioMEMS – TEAM PRESENTATIONS 1/4/2016 – 3/31/2016

  • Follow Blog via Email

    Enter your email address to follow this blog and receive notifications of new posts by email.

    Join 2,041 other subscribers
  • Recent Posts

    • FDA Moves Forward With Its Guidance Framework for Rare Disease Trials: 2026 August 3, 2026
    • Artificial Intelligence TRANSFORMS Medicine, Biotech and Healthcare, How? August 3, 2026
    • In Memoriam: Nobel Laureate J. Michael Bishop for discovery of Retroviral Oncogenes July 31, 2026
    • Companies Actively Engaging Artificial Intellegence for Drug Design: 2026 July 31, 2026
    • AI-Native Drug Discovery Landscape 2026 – How LPBI Group Differentiates in the New Era of Foundation Models July 19, 2026
    • In Memoriam: In Remembrance of Cancer Researchers who passed in 2026 July 13, 2026
    • Urgent Request for Action on Proposed Rule Affecting Federal Funding Grant Review July 7, 2026
    • 2026 Tang Prize in Biopharmaceutical Science Awarded to Three Pioneers of Cellular Immunotherapy Revolutionizing Treatments for Blood Cancers and Solid Tumors July 5, 2026
    • Protected: KOL on Competitive Dynamics: LPBI Group’s Founder’s Radar Screens on AI-in-Health, Life Sciences & BioPharma June 15, 2026
    • Tumor Infiltrating Lymphocytes (TIL) as a first of kind FDA approved immunotherapy for cancer June 12, 2026
  • Archives

  • Categories

  • Meta

    • Log in
    • Entries feed
    • Comments feed
    • WordPress.org
    • 1 2012pharmaceutical
    • 1 sjwilliamspa

Powered by WordPress.com.

WPThemes.


%d